Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome: A Randomized Controlled Trial

NCT07577284 is registered in ClinicalTrials.gov with Taipei Medical University as lead sponsor.

NCT NCT07577284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07577284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AI Chatbot-Enabled ePRO Monitoring and Nurse-Led Self-Management for Early-Stage Cardiovascular-Kidney-Metabolic Syndrome: A Randomized Controlled Trial
Lead sponsor
Taipei Medical University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
July 31, 2029
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular-kidney-metabolic syndrome